ADAPY (Adaptimmune Therapeutics) Days Payable: 275.81 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics Days Payable?

Adaptimmune Therapeutics ADAPY +5.80% Days Payable is 275.81 as of Jun. 2025.

Adaptimmune Therapeutics's average Accounts Payable for the three months ended in Jun. 2025 was $7.56 Mil. Adaptimmune Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2025 was $2.50 Mil. Hence, Adaptimmune Therapeutics's Days Payable for the three months ended in Jun. 2025 was 275.81.

The historical rank and industry rank for Adaptimmune Therapeutics's Days Payable or its related term are showing as below:

ADAPY's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 110.85
* Ranked among companies with meaningful Days Payable only.

Adaptimmune Therapeutics's Days Payable increased from Jun. 2024 (0.00) to Jun. 2025 (275.81). It may suggest that Adaptimmune Therapeutics delayed paying its suppliers.

Adaptimmune Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Days Payable Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 43,852.14

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 747.08 275.81

ADAPY vs BCLI, APRE, JSPR: Days Payable Comparison

For the Biotechnology subindustry, Adaptimmune Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Days Payable falls into.


Adaptimmune Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Adaptimmune Therapeutics's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

Days Payable (A: Dec. 2024 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2023 ) + Accounts Payable (A: Dec. 2024 )) / count ) / Cost of Goods Sold (A: Dec. 2024 )*Days in Period
=( (8.128 + 8.692) / 2 ) / 0.070000000000022*365
=8.41 / 0.070000000000022*365
=43,852.14

Adaptimmune Therapeutics's Days Payable for the quarter that ended in Jun. 2025 is calculated as:

Days Payable (Q: Jun. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Mar. 2025 ) + Accounts Payable (Q: Jun. 2025 )) / count ) / Cost of Goods Sold (Q: Jun. 2025 )*Days in Period
=( (5.701 + 9.418) / 2 ) / 2.501*365 / 4
=7.5595 / 2.501*365 / 4
=275.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 275.81 mean?
Adaptimmune Therapeutics (ADAPY) has a Days Payable of 275.81 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Days Payable too high?
Adaptimmune Therapeutics' current Days Payable is 275.81. The Biotechnology industry median Days Payable is 110.85. Adaptimmune Therapeutics' value of 275.81 is 148.8% above this industry median.
How does Adaptimmune Therapeutics' Days Payable compare to BCLI and APRE?
Adaptimmune Therapeutics' Days Payable of 275.81 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 110.85. Adaptimmune Therapeutics' value of 275.81 is 148.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.85, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adaptimmune Therapeutics's current Days Payable of 275.81 is 148.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Adaptimmune Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 110.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptimmune Therapeutics's current Days Payable is 275.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Days Payable of 275.81. The current Days Payable is 275.81 and 148.8% above the Biotechnology industry median of 110.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Days Payable is 275.81 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].